Development of anti-NXP2 dermatomyositis following Comirnaty COVID-19 vaccination | Postgraduate Medical Journal

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest Content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Adverse drug reactions

Development of anti-NXP2 dermatomyositis following Comirnaty COVID-19 vaccination

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Lee AYS, Lee C, Brown DA, et al

Development of anti-NXP2 dermatomyositis following Comirnaty COVID-19 vaccination

Postgraduate Medical Journal Published Online First: 07 February 2022. doi: 10.1136/postgradmedj-2022-141510